Skip to main content
MethodsX logoLink to MethodsX
. 2019 Aug 30;6:1925–1932. doi: 10.1016/j.mex.2019.08.005

A modified method for rapid quantification of Chlamydia muridarum using Fluorospot

Jonathon Keck 1, James P Chambers 1, Thomas Forsthuber 1, Rishein Gupta 1, Bernard P Arulanandam 1,
PMCID: PMC6745433  PMID: 31538048

Graphical abstract

graphic file with name fx1.jpg

Method name: A modified method for rapid quantification of Chlamydia muridarum using Fluorospot

Keywords: Chlamydia, Fluorospot, Immunospot, Bacterial burdens, Automated counting

Abstract

Although manual enumeration of Chlamydia inclusion forming units is the most widely accepted means of quantification in the field, it is both time consuming and subject to inherent investigator bias. We report here a rapid, i.e., minutes vs. hours, modified automated Fluorospot means of assessment that is linear (<1200 dots per well). Because the Fluorospot enumerated tissue culture plate/well can also be quantified using traditional manual counting, newly derived Fluorospot data can easily be compared to previously established manual enumeration data requiring no new reference norms.

  • Concurrent enumeration of chlamydial IFU using automated and manual methods of counting on same tissue culture plate.

  • Rapid method of counting chlamydial IFU reducing time from hours to minutes.


Specifications Table

Subject Area: Immunology and Microbiology
More specific subject area: Infectious Disease
Method name: A Modified Method for Rapid Quantification of Chlamydia muridarum using Fluorospot
Name and reference of original method: Wang, S., et al., A novel automated method for enumeration of Chlamydia trachomatis inclusion forming units. J Immunol Methods, 2007. 324(1-2): pp. 84-91.
Resource availability: McCoy cells
Black 96-well tissue culture plates with clear bottom (Corning, NY, USA).
Phosphate buffered saline (PBS)
4% (v/v) Saponin (aqueous solution)
Eagle’s Minimum Essential Medium (EMEM)
EMEM with 10% (v/v) FBS (EM-10)
0.05% (w/v) trypsin- Ethylenediaminetetraacetic acid (EDTA) in PBS
Cycloheximide
Gentamicin
Primary (Rabbit anti-C. muridarum outer membrane complex) and secondary (Alexa Fluor (AF)488-conjugated Goat, anti-Rabbit) antibodies
4′,6-diamidino-2-phenylindole (DAPI) nuclear stain

Method details

Chlamydia trachomatis (Ct) is a Gram-negative obligate intracellular pathogen, and currently a leading cause of sexually transmitted infection (STI) worldwide. It is estimated that each day more than 1 million STIs are acquired, and each year some 130 million new Chlamydia infections arise worldwide. In 2014, over 1.4 million cases were reported in the United States taxing the American healthcare system in excess of $500 million in direct medical costs [1]. Due to the asymptomatic nature of Ct infection, an exact number of infected individuals remains unknown [2]. Because Ct is an obligate intracellular bacterium, if left untreated in either symptomatic or asymptomatic patients, infection leads to development of ectopic pregnancy, infertility, and pelvic inflammatory disease (PID) [3,4]. The incidence of Ct has increased worldwide due to lack of organized healthcare infrastructure [5] in Third World developing countries, the unavailability of a vaccine [6,7], and asymptomatic nature of the infection [8,9].

Quantification of Chlamydia inclusion forming units (IFU) is a laborious process requiring growth of confluent monolayers of HeLa or McCoy cells in a 6, 24, 48 or 96 well tissue culture plate format [[10], [11], [12]]. Subsequently, the confluent monolayer must be infected with either genital swab or tissue homogenate material for 20–48 h depending upon serotype. Once established, cells are fixed, stained with serotype specific primary antibody, and subsequently labeled with a fluorophor conjugated secondary antibody. Following labeling, the well contents are typically enumerated manually using a fluorescence microscope, and 5–20 random fields per well. This is both labor intensive and time consuming especially in time course studies requiring multiple periodic sampling over several days. Furthermore, manual quantification may incur an inherent investigator bias toward a preconceived outcome.

Various methods, i.e., PCR, ELISA, and flow cytometry have been employed for quantification of chlamydial IFU [[13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23]]. While these techniques are available and in use, the inability of PCR to discriminate between active or residual infection [20]; the high detection threshold limit required for ELISA [16]; the inability of flow cytometry to provide accurate information regarding size and structure of chlamydial IFU or its location within a cell [17], and the labor intensive nature of immunochemical approaches [16] requiring highly trained technical personnel underscores the need for alternative approaches. We report here a modified, alternative, Fluorospot assay for visual inspection of infected host cells with the added capability of concurrent traditional enumeration allowing comparison of newly derived automated Fluorospot findings to previously well-established manually based Chlamydia norms.

Description of equipment

Scanning of stained cells

CTL Immunospot S6 Universal Analyzer and Immunospot Easy-Count software (Cellular Technology Limited, Cleveland, OH, USA) were used to enumerate positively stained cells. Manufacturer’s recommended analyzer parameter settings: counting mask size (%), 100; normalize counts of mask ‘off’; sensitivity, 200; minimum spot size, 0.0009 sq.mm; maximum spot size, 10.1012 sq.mm; oversized spots were estimated; spot separation, 0.00; diffuseness, small; objects, inverted detailed; over-developed area handling ‘active’; background balance ‘on’; background balance, 100; fill holes ‘off’; hair removal ‘on’; audit spots ‘inactive’; edge effect compensation ‘on’, edge compensation level, 5.0; separation enhancement ‘on’; aperture [pix], 50, and enhancement weight 50.

Experimental procedures

Bacteria

C. muridarum seed stocks were propagated in HeLa 229 cells. At 24 h post infection, HeLa cells were mechanically disrupted using glass beads. Following high-speed centrifugation (40,000 x g for 30 min at 5 °C), bacterial pellets were purified on a Renografin (E.R. Squibb and Sons, Inc., Princeton, NJ, USA) gradient as previously described [24]. Briefly, the cell monolayer was inoculated with stock C. muridarum (1 × 107 IFU), and rocked for 1 h at room temperature. Subsequently, the flask was incubated for 1 h at 37 °C in 5% CO2. Culture media was removed and replaced with fresh EM-10 (Eagle’s Minimum Essential Media (EMEM), with 10% Fetal Bovine Serum, FBS) containing gentamicin (50 μg/mL), and cycloheximide (0.5 μg/mL). The monolayer was monitored for formation of inclusion bodies at ∼20 h post inoculation. Once inclusions are visible microscopically, cells are harvested by scraping the monolayer into a 50 mL canonical tube while on ice. The contents were sonicated on ice for 30 s to release C. muridarum. The cell suspension was centrifuged at 300 × g for 10 min at 5 °C, and the resulting supernatant was centrifuged at 40,000 × g for 30 min. The supernatant was decanted, and pellet material was resuspended in 1 mL Sucrose-Phosphate-Glutamate (SPG) media, and stored at −80 °C until used. Throughout this study, the same C. muridarum seed stock was used.

Mice

Four-six week old C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME), and allowed to acclimate for at least 1 week prior to experimentation. All experiments were conducted in compliance with guidelines issued by the Institutional Animal Care and Use Committee of The University of Texas at San Antonio (approved protocol MU012).

Infection

  • 1

    One day prior to infection, cells were seeded at 5 × 104 cells per well (black 96 well tissue culture plate with a clear bottom, Corning, NY, USA).

  • 2

    The tissue culture plate was incubated overnight at 37 °C in 5No spa% CO2. Cell confluence was observed every few hours on the day of infection, and infection was carried out only if the monolayer was 70–90% confluent.

  • 3

    At confluency, culture media was removed. EMEM (200 u L) was added to each well, and incubated for 30 min at 37 °C in 5% CO2.

  • 4
    Dilution of samples:
    • a
      Elementary Body (EB) stock titration: A1:100 stock dilution was prepared by addition of 10 μL EB stock to 990 μL SPG. A 1:10,000 starting dilution was prepared by adding 10 μL 1:100 stock dilution to 990 μL SPG. A 3-fold serial dilution was set up for as many serial dilutions required.
    • b
      Sample obtained by swabbing: The swab head was clipped and immersed aseptically in a sterile 1.5 mL tube containing 500 μL sterile SPG, and was agitated thoroughly, i.e., vortexed for 1 min. A 100 μL aliquot was removed and transferred to 400 μL sterile SPG (1:5), and mixed by vortexing. For C. trachomatis (all days) and C. muridarum from day 10 onward, a dilution series of 1:50 or 1:100 was used. For C. muridarum (days 1–9), a 1:100 or 1:150 dilution was used due to higher bacterial titers.
  • 5
    EMEM was removed by aspiration, and the monolayer was not washed. Aliquots (50 μL) of each diluent were carefully transferred onto the side of each respective well, placed in a centrifuge plate holder, and centrifuged for 1 h at 500 × g.
    • a
      Following centrifugation, EM-10 of media containing 2 μg/mL cycloheximide and 10 μg/mL gentamicin was added and infected plates were incubated for 20–24 h (C. muridarum) or 40–60 h (C. trachomatis serovars), post initial infection.

Staining

Staining of Chlamydia IFUs was accomplished as previously described [10].

  • 1

    Each wash step consisted of aspiration of the contents of each well followed by addition of 200 μL 1X Phosphate Buffered Saline (PBS), and immediate removal of the well contents by aspiration.

  • 2

    Cells were fixed with 150 μL 4% (v/v) paraformaldehyde for 10 min at room temperature followed by aspiration of well contents.

  • 3

    Perforation of cells was achieved by addition of 150 μL 4% saponin (v/v) for 30 min at room temperature. The contents of the well were removed by aspiration, and fixed cells washed 2X’s with PBS.

Note: 150 μL 0.1% (v/v) Triton-X100 in PBS can be used, but greater repeatability was observed with 4% saponin.

  • 4

    Blocking was achieved by addition of 200 μL EM-10 media for 30 min at room temperature overnight at 4 °C followed by aspiration.

  • 5

    100 μL primary antibody (rabbit anti-C. muridarum outer membrane complex was kindly provided by Dr. Guangming Zhong, Department of Microbiology, Immunology, and Molecular Genetics, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229) diluted 1:2000 in EM-10 media was added, incubated at 37 °C for 1 h, and washed 3Xs with PBS.

  • 6

    100 μL secondary antibody (AF488-conjugated goat anti-rabbit, Sigma Chemical, St. Louis, MO) diluted 1:400 and 4′,6-diamidino-2-phenylindole (DAPI, Sigma Chemical, St. Louis, MO) diluted 1:1000 in blocking EM-10 media was added to each well, incubated at 37 °C for 1 h, and washed 3 times.

  • 7

    Following addition of 50 μL 1X PBS, IFUs were enumerated.

Enumeration

Manual

  • 1

    Starting with the highest dilution at 10-X magnification, the number of inclusions in the center, upper right, lower right, lower left, and upper left sections of the well were counted.

  • 2

    If the cell monolayer does not cover the entire field or has swaths missing, the field was moved past the inadequate area until a full monolayer came into view.

  • 3

    If fewer than 5 inclusions were visible per field at the lowest magnification, inclusions present in three wells were counted. Conversely, if more than 30 inclusions were visible, the next highest magnification was used and inclusions were counted.

  • 4

    If the sample infection rate reached 100% (one inclusion per cell), these samples were not counted.

  • 5

    Each dilution was evaluated at the lowest magnification increasing the magnification accordingly. Five fields for each well were counted. The dilution and magnification for each count was recorded.

  • 6

    Determination of IFU/mL in a given sample was based on the mean number of inclusions per view, the ratio of the view area to that of the total well, dilution factor, and inoculum volume as described below [13].

IFU/mL = (IFU counted/Fields counted) (Dilution)[πr2/π(A/2)2]/Inoculation vol (mL)−1 (1)

Where: r2 = (well radius)2

FOV = field of vision

A = FOV eye piece/objective magnification

π(A/2)2 = Area of radius viewed

Automated

  • 1

    Quantification was achieved by scanning using the CTL Immunospot S6 Universal Analyzer.

  • 2

    Determination of IFU/mL was achieved using the Easy-Count Software as described below:

IFU/mL = (Counts/well)(Dilution)/Inoculation vol (mL)−1 (2)

Statistical analyses

Statistical analyses were performed using Prism 7 software (GraphPad, La Jolla, CA, USA). All data shown are representative of at least 2 experiments, and each experiment shown was analyzed independently. For multiple comparisons, 2-way ANOVA with Tukey’s post hoc test (parametric distribution) and Kruskal-Wallis post hoc test (nonparametric distribution) were used. Differences were considered statistically significant if P < 0.05.

Results

Using a black 96-well plate with a clear bottom, McCoy fibroblast cells were seeded at 5 × 104 cells per well, incubated overnight, and subsequently infected with 2–8 × 108 C. muridarum per well. Fluorescence microscopy was used to evaluate IFUs present, and cell confluency (Figs. 1a and b, respectively). Shown in Fig. 1c is a merged image of Fig. 1a and b showing Chlamydia infected confluent cells. Shown in Fig. 2a is a CTL Immunospot S6 Universal Analyzer imaged 96 well plate. Replicates (1 and 2; 3 and 4; 5 and 6; 7 and 8; 9 and 10; 11 and 12) of C. muridarum infected cells (Row A-left to right: inocula containing 1.19 × 103, 4.71 × 103, 1.05 × 104, 1.85 × 104, 2.86 × 104, and 4.09 × 104 IFUs), respectively, were serially diluted 2-fold, giving rise to rows B-H. Shown in Fig. 2b is a representative CTL Immunospot S6 Universal Analyzer imaged Chlamydia infected well compared to a representative quantitated well derived image using the Immunospot Easy-Count Software, i.e., 1567 Chlamydia IFU counted (Fig. 2c). Shown in Fig. 2d is a graphical analysis of serially diluted Chlamydia inocula. With exception of the starting samples containing 1.19 × 103 IFUs (black circles), a nonlinear relationship between IFUs present and dots/well detected was observed for all starting samples as well as their respective diluents. Although the range of linearity for the 1.19 × 103 containing sample is narrow, i.e., approximately 1200 down to 200 dots/well, these data points do reflect a general linear relationship between IFU present and dots/well detected supporting the usefulness of this enumeration approach. Shown in Fig. 2e is comparison of IFU/mL values obtained manually to that obtained using the CTL Immunospot S6 Universal Analyzer. Based upon the linearity observed in Fig. 2d (Black dots), results shown in Fig. 2e were based upon enumeration values which fell well within the range of linearity, i.e., <1200 IFUs prior to calculation of IFU/mL indicating no significant difference between manual and automated approaches. Consistent with in vitro Chlamydia infected McCoy fibroblast cells (Fig. 1, Fig. 2), no quantitative difference was observed when comparing automated and manual IFU evaluation of in vivo, i.e., intravaginally inoculated Chlamydia monitored by genital tract swabbing (Fig. 3). Results shown in Fig. 3 were based upon enumeration values (mean ± SD = 15.5 ± 9.2) which fell within the range of linearity prior to calculation of IFU/mL.

Fig. 1.

Fig. 1

Fluorescence microscopy of Chlamydia infected HELA 229 cells. Representative microscopic fields of Chlamydia infected host cells stained with (a) AF488-conjugated secondary antibody, (b) DAPI nuclear reagent, and (c) merged image. The white bar represents 100 μm. Infection and fluorescence staining of Chlamydia and host cells was carried out as previously described under 'Experimental Procedures'.

Fig. 2.

Fig. 2

Enumeration of Chlamydia. Cells were infected with Chlamydia at a MOI = 1, and serially diluted 2-fold (B–H). (a) Entire 96 well plate imaged with the CTL Immunospot S6 Universal Analyzer. Replicates (1 and 2; 3 and 4; 5 and 6; 7 and 8; 9 and 10; 11 and 12) of C. muridarum infected cells (Row A-left to right) contained 1.19 × 103, 4.71 × 103, 1.05 × 104, 1.85 × 104, 2.86 × 104, and 4.09 × 104 IFUs, respectively, and were serially diluted 2-fold giving rise to rows B–H. (b) A representative CTL Immunospot S6 Universal Analyzer imaged infected well. (c) A representative Immunospot Easy-Count Software quantitated well derived from the CTL Immunospot S6 Universal Analyzer image. (d) Graphical analysis of 2-fold serial stock dilutions. Inocula (IFU x 103): Black closed circles, 1.19; Orange closed diamonds, 4.71; Purple inverted closed triangles, 10.5; Green closed triangles, 18.5; Red closed squares, 28.6; Blue closed circles, 40.9. Starting, undiluted sample = A. The bar on the ‘x’ axis represents the respective 2-fold dilution steps (B–H). (e) Comparison of manual and automated quantitation. Using equations 1 and 2 to calculate IFU/mL, the bar graphs represent the average of all values derived for all 96 wells. Infection of cells, fluorescence labeling (Fluorospot ELISA), and calculation of Chlamydia IFU values was carried out as previously described under 'Experimental Procedures'. NS = not significant. P < 0.05 Two-way ANOVA with Sidak. Graphical analysis is representative of 2 independent experiments.

Fig. 3.

Fig. 3

In vivo Chlamydia challenge-comparison of manual and automated quantitation. Mice were challenged intravaginally with 5 × 104Chlamydia IFU. Respective genital tracts were swabbed 9 days post infection. Individual well comparison using manual (Blue closed squares) and automated (Orange closed circles) quantitation. Each data pair represents a different animal. IFU/mL were calculated according to Eqs. (1) and (2).

Discussion

Considering the high incidence of chlamydial infections [8], manual counting of IFU by microscopy [10,24] is not a practical, high throughput, diagnostic approach nor is it adaptable for large scale screening required for development of vaccines and/or antibiotic candidates. Manual, microscopic counting is very labor/cost intensive requiring trained laboratory personnel, and is inherently prone to technician bias as it requires selection of microscopic fields for enumeration. To overcome- these logistical concerns, our findings provide a fast, quantifiable alternate methodology. Values reported here were derived from experimental conditions resulting in confluent reporter cell monolayers. However, a reduced field of view, i.e., 50% analogous to a nonconfluent monolayer resulted in proportionately reduced IFU values when compared to the full field view, i.e., 100% (Data not shown). The method reported here is also amendable to further simplification, i.e., single antibody based direct fluorescence enumeration using AF-488 conjugated antibody targeting specific surface antigens.

Although automation overcomes the pitfalls of manual counting, the gold standard for determining infectious Chlamydia sp., is that of manual assessment, i.e., counting by technical personnel. The advantage of the approach reported here resides in further modification of the Fluorospot assay using a black 96-well plate with a clear bottom. Cost effective methodologies, i.e., PCR and flow cytometry have been used for chlamydial detection. However, limitations/drawbacks of these techniques highlight the need for alternative assays. The Florospot system is not near as expensive as more sophisticated instrumentation, i.e., whole animal in vivo imaging [25] and/or imaging flow cytometry systems [26], that could be employed for chlamydial burden detection in infected samples.

Author contributions

JK, TF, JPC, RG, BPA conceptualized the study. JK carried out the experimentation. JK, TF, JPC, RG, and BPA analyzed the experimental findings. JK, RG, JPC, and BPA drafted, and edited the manuscript.

Declaration of Competing Interest

Authors declare that they have no competing interests.

Acknowledgments

This work was supported by the National Institutes of Health (NIH) grant IR03AI11771401A1, and the Army Research Office (Department of Defense contract No. W911NF-11-1-0136).

Contributor Information

Jonathon Keck, Email: Jonathon.Keck@utsa.edu.

James P. Chambers, Email: James.Chambers@utsa.edu.

Thomas Forsthuber, Email: Thomas.Forsthuber@utsa.edu.

Rishein Gupta, Email: Rishein.Gupta@utsa.edu.

Bernard P. Arulanandam, Email: Bernard.Arulanandam@utsa.edu.

References

  • 1.Owusu-Edusei K., Jr. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex. Transm. Dis. 2013;40:197–201. doi: 10.1097/OLQ.0b013e318285c6d2. [DOI] [PubMed] [Google Scholar]
  • 2.de la Maza L.M. Update on Chlamydia trachomatis vaccinology. Clin. Vaccine Immunol. 2017;24:e00543–16. doi: 10.1128/CVI.00543-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ammerdorffer A. Chlamydia trachomatis and Chlamydia-like bacteria: new enemies of human pregnancies. Curr. Opin. Infect. Dis. 2017;30:289–296. doi: 10.1097/QCO.0000000000000369. [DOI] [PubMed] [Google Scholar]
  • 4.Haggerty C.L. Risk of sequelae after Chlamydia trachomatis genital infection in women. J. Infect. Dis. 2010;201(2):S134–155. doi: 10.1086/652395. [DOI] [PubMed] [Google Scholar]
  • 5.Rekart M.L. Chlamydia public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy. J. Infect. Dis. 2013;207:30–38. doi: 10.1093/infdis/jis644. [DOI] [PubMed] [Google Scholar]
  • 6.Zhong G. National institute of allergy and infectious diseases workshop report: “Chlamydia vaccines: the way forward”. Vaccine. 2017 doi: 10.1016/j.vaccine.2017.10.075. pii: S0264-410X(17)31483-4. [DOI] [PubMed] [Google Scholar]
  • 7.Phillips S. Seventy years of Chlamydia vaccine research - limitations of the past and directions for the future. Front. Microbiol. 2019;10:70. doi: 10.3389/fmicb.2019.00070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Brunham R.C. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J. Infect. Dis. 2005;192:1836–1844. doi: 10.1086/497341. [DOI] [PubMed] [Google Scholar]
  • 9.Seale A. Assessing process, content, and politics in developing the global health sector strategy on sexually transmitted infections 2016–2021: implementation opportunities for policymakers. PLoS Med. 2017;14 doi: 10.1371/journal.pmed.1002330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Conrad T.A. The chromosome-encoded hypothetical protein TC0668 is an upper genital tract pathogenicity factor of Chlamydia muridarum. Infect. Immun. 2016;84:467–479. doi: 10.1128/IAI.01171-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chen C. In vitro passage selects for Chlamydia muridarum with enhanced infectivity in cultured cells but attenuated pathogenicity in mouse upper genital tract. Infect. Immun. 2015;83:1881–1892. doi: 10.1128/IAI.03158-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gupta R. Antigen specific immune response in Chlamydia muridarum genital infection is dependent on murine microRNAs-155 and -182. Oncotarget. 2016;7:64726–64742. doi: 10.18632/oncotarget.11461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang S. A novel automated method for enumeration of Chlamydia trachomatis inclusion forming units. J. Immunol. Methods. 2007;324:84–91. doi: 10.1016/j.jim.2007.05.004. [DOI] [PubMed] [Google Scholar]
  • 14.Kaser T. Flow cytometry as an improved method for the titration of Chlamydiaceae and other intracellular bacteria. Cytometry A. 2016;89:451–460. doi: 10.1002/cyto.a.22822. [DOI] [PubMed] [Google Scholar]
  • 15.Borges V. Normalization strategies for real-time expression data in Chlamydia trachomatis. J. Microbiol. Methods. 2010;82:256–264. doi: 10.1016/j.mimet.2010.06.013. [DOI] [PubMed] [Google Scholar]
  • 16.Poikonen K. Quantification of Chlamydia pneumoniae in cultured human macrophages and HL cells: comparison of real-time PCR, immunofluorescence and ELISA methods. APMIS. 2010;118:45–48. doi: 10.1111/j.1600-0463.2009.02557.x. [DOI] [PubMed] [Google Scholar]
  • 17.Grun M. Flow cytometric quantification of chlamydial infection in cell culture. J. Microbiol. Methods. 2009;78:360–362. doi: 10.1016/j.mimet.2009.06.016. [DOI] [PubMed] [Google Scholar]
  • 18.McGowin C.L. High-throughput multistrain polymerase chain reaction quantification of Chlamydia trachomatis from clinical and preclinical urogenital specimens. Diagn. Microbiol. Infect. Dis. 2009;64:117–123. doi: 10.1016/j.diagmicrobio.2009.01.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rupp J. Single-nucleotide-polymorphism-specific PCR for quantification and discrimination of Chlamydia pneumoniae genotypes by use of a “locked” nucleic acid. Appl. Environ. Microbiol. 2006;72:3785–3787. doi: 10.1128/AEM.72.5.3785-3787.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jalal H. Development and validation of a rotor-gene real-time PCR assay for detection, identification, and quantification of Chlamydia trachomatis in a single reaction. J. Clin. Microbiol. 2006;44:206–213. doi: 10.1128/JCM.44.1.206-213.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ciervo A. Identification and quantification of Chlamydia pneumoniae in human atherosclerotic plaques by LightCycler real-time-PCR. Mol. Cell. Probes. 2003;17:107–111. doi: 10.1016/s0890-8508(03)00028-8. [DOI] [PubMed] [Google Scholar]
  • 22.Blocker M.E. Quantification of Chlamydia trachomatis elementary bodies in urine by ligase chain reaction. J. Clin. Microbiol. 2002;40:3631–3634. doi: 10.1128/JCM.40.10.3631-3634.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lockett S.J. Automated fluorescence image cytometry. DNA quantification and detection of chlamydial infections. Anal. Quant. Cytol. Histol. 1991;13:27–44. [PubMed] [Google Scholar]
  • 24.Arkatkar T. Murine MicroRNA-214 regulates intracellular adhesion molecule (ICAM1) gene expression in genital Chlamydia muridarum infection. Immunology. 2015;145:534–542. doi: 10.1111/imm.12470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gupta R. In vivo whole animal body imaging reveals colonization of Chlamydia muridarum to the lower genital tract at early stages of infection. Mol. Imaging Biol. 2014;16:635–641. doi: 10.1007/s11307-014-0732-5. [DOI] [PubMed] [Google Scholar]
  • 26.Haridas V. Imaging flow cytometry analysis of intracellular pathogens. Methods. 2017;112:91–104. doi: 10.1016/j.ymeth.2016.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from MethodsX are provided here courtesy of Elsevier

RESOURCES